ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 137 of 179 for:    "Arthritis, Juvenile Rheumatoid"

ARTEMIS Synovial Markers in Arthritis Childhood (ARTEMIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02505828
Recruitment Status : Unknown
Verified June 2015 by University Hospital, Montpellier.
Recruitment status was:  Active, not recruiting
First Posted : July 22, 2015
Last Update Posted : July 22, 2015
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory arthritis. The investigators will use for this analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The investigators will use one marker or a score with biological and clinical data to discriminate arthritis of infectious and inflammatory etiology.

Condition or disease Intervention/treatment Phase
Septic Arthritis Juvenile Idiopathic Arthritis Procedure: Articular punction, salivary samples, blood sample Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: ARTEMIS Synovial Markers in Arthritis Childhood
Study Start Date : April 2015
Estimated Primary Completion Date : April 2017
Estimated Study Completion Date : April 2017


Arm Intervention/treatment
Septic arthritis
with bacteriological identification
Procedure: Articular punction, salivary samples, blood sample
Other Names:
  • Proteomic analysis
  • Cytokine dosage
  • Monocyte

Juvenile idiopathic arthritis
beyond the ILAR (International League of Associations for Rheumatology) definition
Procedure: Articular punction, salivary samples, blood sample
Other Names:
  • Proteomic analysis
  • Cytokine dosage
  • Monocyte




Primary Outcome Measures :
  1. Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis. [ Time Frame: 1 day ]
    Identify blood sampling biomarkers of Arthritis childhood



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Septic arthritis with bacteriological identification
  • Juvenile idiopathic arthritis beyond the ILAR definition
  • Having acute arthritis requiring an articular draining
  • Child benefiting from a national insurance scheme
  • Collection of the consent of the parents or the legal representative

Exclusion Criteria:

  • Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins lower than 70 %, activated partial thromboplastin times (APTT)> 1,5
  • Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding the articular draining.
  • Treatment by antibiotic begun more than 24 hours before the draining.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02505828


Locations
France
Hôpital Arnaud de Villeneuve
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
Investigators
Principal Investigator: Eric EJ JEZIORSKI, MD, PhD Montpellier University Hospital

Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT02505828     History of Changes
Other Study ID Numbers: 93612
2014-A01561-46 ( Registry Identifier: ID RCB )
First Posted: July 22, 2015    Key Record Dates
Last Update Posted: July 22, 2015
Last Verified: June 2015

Keywords provided by University Hospital, Montpellier:
Arthritis
septic
Juvenile idiopathic arthritis
diagnosis
proteomic
cytokine
monocytes

Additional relevant MeSH terms:
Arthritis
Arthritis, Juvenile
Arthritis, Infectious
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Infection